These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 37087871)

  • 1. Efficacy of the modified vaccinia Ankara virus vaccine and the replication-competent vaccine ACAM2000 in monkeypox prevention.
    Kandeel M; Morsy MA; Abd El-Lateef HM; Marzok M; El-Beltagi HS; Al Khodair KM; Albokhadaim I; Venugopala KN
    Int Immunopharmacol; 2023 Jun; 119():110206. PubMed ID: 37087871
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase 3 Efficacy Trial of Modified Vaccinia Ankara as a Vaccine against Smallpox.
    Pittman PR; Hahn M; Lee HS; Koca C; Samy N; Schmidt D; Hornung J; Weidenthaler H; Heery CR; Meyer TPH; Silbernagl G; Maclennan J; Chaplin P
    N Engl J Med; 2019 Nov; 381(20):1897-1908. PubMed ID: 31722150
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serological responses to the MVA-based JYNNEOS monkeypox vaccine in a cohort of participants from the Democratic Republic of Congo.
    Priyamvada L; Carson WC; Ortega E; Navarra T; Tran S; Smith TG; Pukuta E; Muyamuna E; Kabamba J; Nguete BU; Likafi T; Kokola G; Lushima RS; Tamfum JM; Okitolonda EW; Kaba DK; Monroe BP; McCollum AM; Petersen BW; Satheshkumar PS; Townsend MB
    Vaccine; 2022 Nov; 40(50):7321-7327. PubMed ID: 36344361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of Biological, Pharmacological Characteristics, Indications, Contraindications and Adverse Effects of JYNNEOS and ACAM2000 Monkeypox Vaccines.
    Meo SA; Al-Masri AA; Klonoff DC; Alshahrani AN; Al-Khlaiwi T
    Vaccines (Basel); 2022 Nov; 10(11):. PubMed ID: 36423066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of JYNNEOS (Smallpox and Monkeypox Vaccine, Live, Nonreplicating) for Preexposure Vaccination of Persons at Risk for Occupational Exposure to Orthopoxviruses: Recommendations of the Advisory Committee on Immunization Practices - United States, 2022.
    Rao AK; Petersen BW; Whitehill F; Razeq JH; Isaacs SN; Merchlinsky MJ; Campos-Outcalt D; Morgan RL; Damon I; Sánchez PJ; Bell BP
    MMWR Morb Mortal Wkly Rep; 2022 Jun; 71(22):734-742. PubMed ID: 35653347
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estimated Effectiveness of JYNNEOS Vaccine in Preventing Mpox: A Multijurisdictional Case-Control Study - United States, August 19, 2022-March 31, 2023.
    Dalton AF; Diallo AO; Chard AN; Moulia DL; Deputy NP; Fothergill A; Kracalik I; Wegner CW; Markus TM; Pathela P; Still WL; Hawkins S; Mangla AT; Ravi N; Licherdell E; Britton A; Lynfield R; Sutton M; Hansen AP; Betancourt GS; Rowlands JV; Chai SJ; Fisher R; Danza P; Farley M; Zipprich J; Prahl G; Wendel KA; Niccolai L; Castilho JL; Payne DC; Cohn AC; Feldstein LR; ;
    MMWR Morb Mortal Wkly Rep; 2023 May; 72(20):553-558. PubMed ID: 37200229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Receipt of First and Second Doses of JYNNEOS Vaccine for Prevention of Monkeypox - United States, May 22-October 10, 2022.
    Kriss JL; Boersma PM; Martin E; Reed K; Adjemian J; Smith N; Carter RJ; Tan KR; Srinivasan A; McGarvey S; McGehee J; Henderson D; Aleshire N; Gundlapalli AV
    MMWR Morb Mortal Wkly Rep; 2022 Oct; 71(43):1374-1378. PubMed ID: 36301741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety Monitoring of JYNNEOS Vaccine During the 2022 Mpox Outbreak - United States, May 22-October 21, 2022.
    Duffy J; Marquez P; Moro P; Weintraub E; Yu Y; Boersma P; Donahue JG; Glanz JM; Goddard K; Hambidge SJ; Lewin B; Lewis N; Rouse D; Shimabukuro T
    MMWR Morb Mortal Wkly Rep; 2022 Dec; 71(49):1555-1559. PubMed ID: 36480476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced Risk for Mpox After Receipt of 1 or 2 Doses of JYNNEOS Vaccine Compared with Risk Among Unvaccinated Persons - 43 U.S. Jurisdictions, July 31-October 1, 2022.
    Payne AB; Ray LC; Cole MM; Canning M; Houck K; Shah HJ; Farrar JL; Lewis NM; Fothergill A; White EB; Feldstein LR; Roper LE; Lee F; Kriss JL; Sims E; Spicknall IH; Nakazawa Y; Gundlapalli AV; Shimabukuro T; Cohen AL; Honein MA; Mermin J; Payne DC
    MMWR Morb Mortal Wkly Rep; 2022 Dec; 71(49):1560-1564. PubMed ID: 36480479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. JYNNEOS Vaccination Coverage Among Persons at Risk for Mpox - United States, May 22, 2022-January 31, 2023.
    Owens LE; Currie DW; Kramarow EA; Siddique S; Swanson M; Carter RJ; Kriss JL; Boersma PM; Lee FC; Spicknall I; Hurley E; Zlotorzynska M; Gundlapalli AV
    MMWR Morb Mortal Wkly Rep; 2023 Mar; 72(13):342-347. PubMed ID: 36995962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preventing the Next Pandemic: Is Live Vaccine Efficacious against Monkeypox, or Is There a Need for Killed Virus and mRNA Vaccines?
    Abdelaal A; Reda A; Lashin BI; Katamesh BE; Brakat AM; Al-Manaseer BM; Kaur S; Asija A; Patel NK; Basnyat S; Rabaan AA; Alhumaid S; Albayat H; Aljeldah M; Shammari BRA; Al-Najjar AH; Al-Jassem AK; AlShurbaji ST; Alshahrani FS; Alynbiawi A; Alfaraj ZH; Alfaraj DH; Aldawood AH; Sedhai YR; Mumbo V; Rodriguez-Morales AJ; Sah R
    Vaccines (Basel); 2022 Aug; 10(9):. PubMed ID: 36146497
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low levels of monkeypox virus-neutralizing antibodies after MVA-BN vaccination in healthy individuals.
    Zaeck LM; Lamers MM; Verstrepen BE; Bestebroer TM; van Royen ME; Götz H; Shamier MC; van Leeuwen LPM; Schmitz KS; Alblas K; van Efferen S; Bogers S; Scherbeijn S; Rimmelzwaan GF; van Gorp ECM; Koopmans MPG; Haagmans BL; GeurtsvanKessel CH; de Vries RD
    Nat Med; 2023 Jan; 29(1):270-278. PubMed ID: 36257333
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Demographic and Clinical Characteristics of Mpox in Persons Who Had Previously Received 1 Dose of JYNNEOS Vaccine and in Unvaccinated Persons - 29 U.S. Jurisdictions, May 22-September 3, 2022.
    Farrar JL; Lewis NM; Houck K; Canning M; Fothergill A; Payne AB; Cohen AL; Vance J; Brassil B; Youngkin E; Glenn B; Mangla A; Kupferman N; Saunders K; Meza C; Nims D; Soliva S; Blouse B; Henderson T; Banerjee E; White B; Birn R; Stadelman AM; Abrego M; McLafferty M; Eberhart MG; Pietrowski M; De León SM; Creegan E; Diedhiou A; Wiedeman C; Murray-Thompson J; McCarty E; Marcinkevage J; Kocharian A; Torrone EA; Ray LC; Payne DC;
    MMWR Morb Mortal Wkly Rep; 2022 Dec; 71(5152):1610-1615. PubMed ID: 36580416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes of post-exposure vaccination by modified vaccinia Ankara to prevent mpox (formerly monkeypox): a retrospective observational study in Lyon, France, June to August 2022.
    Merad Y; Gaymard A; Cotte L; Perpoint T; Alfaiate D; Godinot M; Becker A; Cannesson O; Batalla AS; Oria-Yassir F; Landré S; Morfin F; Bouscambert M; Valour F; Ader F; Conrad A
    Euro Surveill; 2022 Dec; 27(50):. PubMed ID: 36695469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence of Monkeypox Among Unvaccinated Persons Compared with Persons Receiving ≥1 JYNNEOS Vaccine Dose - 32 U.S. Jurisdictions, July 31-September 3, 2022.
    Payne AB; Ray LC; Kugeler KJ; Fothergill A; White EB; Canning M; Farrar JL; Feldstein LR; Gundlapalli AV; Houck K; Kriss JL; Lewis NM; Sims E; Smith DK; Spicknall IH; Nakazawa Y; Damon IK; Cohn AC; Payne DC
    MMWR Morb Mortal Wkly Rep; 2022 Oct; 71(40):1278-1282. PubMed ID: 36201401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world effectiveness of a single dose of mpox vaccine in males.
    Wolff Sagy Y; Zucker R; Hammerman A; Markovits H; Arieh NG; Abu Ahmad W; Battat E; Ramot N; Carmeli G; Mark-Amir A; Wagner-Kolasko G; Duskin-Bitan H; Yaron S; Peretz A; Arbel R; Lavie G; Netzer D
    Nat Med; 2023 Mar; 29(3):748-752. PubMed ID: 36720271
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced immunogenicity and protective effect conferred by vaccination with combinations of modified vaccinia virus Ankara and licensed smallpox vaccine Dryvax in a mouse model.
    Meseda CA; Garcia AD; Kumar A; Mayer AE; Manischewitz J; King LR; Golding H; Merchlinsky M; Weir JP
    Virology; 2005 Sep; 339(2):164-75. PubMed ID: 15993917
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial.
    Ishola D; Manno D; Afolabi MO; Keshinro B; Bockstal V; Rogers B; Owusu-Kyei K; Serry-Bangura A; Swaray I; Lowe B; Kowuor D; Baiden F; Mooney T; Smout E; Köhn B; Otieno GT; Jusu M; Foster J; Samai M; Deen GF; Larson H; Lees S; Goldstein N; Gallagher KE; Gaddah A; Heerwegh D; Callendret B; Luhn K; Robinson C; Leyssen M; Greenwood B; Douoguih M; Leigh B; Watson-Jones D;
    Lancet Infect Dis; 2022 Jan; 22(1):97-109. PubMed ID: 34529963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine.
    Shen X; Basu R; Sawant S; Beaumont D; Kwa SF; LaBranche C; Seaton KE; Yates NL; Montefiori DC; Ferrari G; Wyatt LS; Moss B; Alam SM; Haynes BF; Tomaras GD; Robinson HL
    J Virol; 2017 Dec; 91(24):. PubMed ID: 29021394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccinia-Virus-Based Vaccines Are Expected to Elicit Highly Cross-Reactive Immunity to the 2022 Monkeypox Virus.
    Ahmed SF; Sohail MS; Quadeer AA; McKay MR
    Viruses; 2022 Sep; 14(9):. PubMed ID: 36146766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.